Disc Medicine, Inc. (IRON)
NASDAQ: IRON · IEX Real-Time Price · USD
41.62
-4.85 (-10.44%)
At close: Jul 2, 2024, 4:00 PM
43.70
+2.08 (5.00%)
After-hours: Jul 2, 2024, 7:08 PM EDT
Disc Medicine Employees
Disc Medicine had 74 employees as of December 31, 2023. The number of employees increased by 28 or 60.87% compared to the previous year.
Employees
74
Change (1Y)
28
Growth (1Y)
60.87%
Revenue / Employee
n/a
Profits / Employee
-$1,089,149
Market Cap
1.23B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 74 | 28 | 60.87% |
Dec 31, 2022 | 46 | 13 | 39.39% |
Dec 31, 2021 | 33 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Brookdale Senior Living | 36,000 |
U.S. Physical Therapy | 6,720 |
Tilray Brands | 1,600 |
Schrödinger | 867 |
Alphatec Holdings | 839 |
Supernus Pharmaceuticals | 652 |
Arcus Biosciences | 577 |
BioCryst Pharmaceuticals | 536 |
IRON News
- 18 days ago - Disc Medicine Announces Underwritten Offering of Common Stock - GlobeNewsWire
- 18 days ago - Disc Medicine Presents Positive Clinical Data Across Portfolio at the European Hematology Association (EHA) 2024 Congress - GlobeNewsWire
- 4 weeks ago - Disc Medicine to Participate in the Jefferies Global Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress - GlobeNewsWire
- 7 weeks ago - Disc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference - GlobeNewsWire
- 7 weeks ago - Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - Top 3 Health Care Stocks You'll Regret Missing This Month - Humana (NYSE:HUM), Disc Medicine (NASDAQ:IRON) - Benzinga
- 3 months ago - Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) - GlobeNewsWire